Andrew Justin Stewart Coats

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Andrew Justin Stewart Coats
Andrew Coats-2010.jpg
Andrew Justin Stewart Coats, c. 2010
Born (1958-02-01) 1 February 1958 (age 56)
Melbourne, Australia
Nationality Australian
British
Education University of Oxford
Cambridge University
London Business School
Known for Chronic heart failure research
Medical career
Profession Academic
senior university administrator
Institutions University of Oxford
Royal Brompton Hospital of Imperial College London
University of Sydney
Norwich Research Park
University of Warwick
Monash University
Specialism Cardiology
Notable prizes Linacre Medal
Michael L Pollock Award (inaugural recipient), American Heart Association

Andrew Justin Stewart Coats (born 1 February 1958) is an Australian–British academic cardiologist who has particular interest in the management of heart failure. His research turned established teaching on its head and promoted exercise training (rather than bed rest) as a treatment for chronic heart failure. He was instrumental in describing the "muscle hypothesis" of heart failure. In addition to this, Coats is also a successful fundraiser, university administrator, and inventor. His Imperial College patents have formed the basis of companies specialising in the treatment of cachexia (Myotec[1][2] and PsiOxus[3]).

Early life and education[edit]

Andrew J. Stewart Coats was born and raised in Melbourne. His father, Douglas A. Coats, was a Professor of Resuscitation who first described essential fatty acids.[4]

Coats was educated at Melbourne Grammar School, where he was proxime accessit Head of School and a School Officer; St Catherine's College, Oxford, where he earned a B.A. in Physiological Sciences with First-Class Honours and won the Rose Prize; and Clare College, Cambridge, where he read medicine, earning a M.B. B.Chir., and was top of his year with two distinctions.

Career[edit]

Medical career[edit]

After qualifying in medicine in 1980, Coats started his career at St Vincent's Hospital, Melbourne under Professor David Penington and then the University of Oxford under Professor Peter Sleight. In 1991, he was appointed Senior Lecturer, supported by the British Heart Foundation, at the National Heart and Lung Institute [NHLI] under Professor Philip Poole-Wilson.

In 1996, he was appointed the Viscount Royston Professor of Cardiology at Imperial College. He was also honorary consultant physician at the Royal Brompton Hospital in London, and its Clinical Director for Cardiology and its Associate Medical Director.

In 2002, Coats became the 17th Dean of the Faculty of Medicine at the University of Sydney.[5] In 2006, he was appointed Deputy Vice-Chancellor (External Communications) of the University of Sydney.[6]

In 2009, Coats was appointed the second Norwich Research Park Professor-at-Large, second to Baron Solly Zuckerman.[7][8]

In 2011, Coats was appointed chief executive officer of the Norwich Research Park.

In 2013, he will take up the position of Joint Academic Vice-President of Monash University, Australia and the University of Warwick, UK.[9][10][11]

Research career[edit]

Coats commenced his research career in hypertension, where he did some of the early work on the clinical value of 24-hour ambulatory blood pressure monitoring.[12][13] His subsequent career, forming the bulk of his more than 550 research papers, has been in the field of heart failure where he conducted the first ever randomised trial of exercise training in chronic heart failure.[14]

He coined the term "The Muscle Hypothesis", the now accepted explanation for the generation of exercise-limiting symptoms in chronic heart failure, but at the time a radical theory.[15]

He has been chairman or a member of the steering committee of many large-scale international drug trials that have influenced treatment of cardiovascular disease. These include the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Trial,[16] OPTIMAAL (angiotensin receptor antagonist in heart failure),[17] and SENIORS (management of heart failure in the elderly).[18]

He has published widely, with over 450 items on PubMed as of February 2011[19] and has been Editor-in-Chief of the International Journal of Cardiology since 1999.

National and international work[edit]

Coats was appointed chair of Australia's peak policy body for Health Informatics, the Australian Health Information Council (AHIC). He sat on many committees and chaired the New South Wales Ministerial Advisory Committee on Health and Medical Research (MACMHR).[20] In his three years as Deputy Vice-Chancellor in charge of External Relations and Development at Sydney, the university achieved the highest ever fund-raising total for any Australian university, in excess of A$50 million per year.[21]

Commercial career[edit]

Coats completed an M.B.A. at London Business School and subsequently became a Fellow of the Australian Institute of Company Directors and a member of London's Institute of Directors. He has also been a board director of a number of private and public companies, including Myotec,[22] PsiOxus,[23] Lone Star Heart Inc.,[24] Centenary Institute, the Heart Research Institute, Cardiodirect (UK) Limited, the Woolcock Institute of Medical Research,[25] and the George Institute of International Health.[26][27]

Family[edit]

Coats has two brothers, one of whom, Peter, works for Minter Ellison in Melbourne. Peter has previously been the firm's managing partner over a number of years, specialising in asbestos litigation, coronial inquests, liability claims and occupational health and safety prosecutions, and insurance law and is a graduate of the Melbourne Law School (LL.B.) and University of Melbourne (B.A.).[28][29]

Awards[edit]

References[edit]

  1. ^ "Innovations spin-out Myotec merges with Hybrid Biosystems to form PsiOxus Therapeutics; £3.6m new funding to develop therapeutic pipeline". Imperial Innovations. 15 December 2010. 
  2. ^ "Innovations leads £5.6m investment in Myotec to fund treatments for muscle wasting disease". Imperial Innovations. 1 March 2010. 
  3. ^ "PsiOxus – Advisory Board". PsiOxus. 
  4. ^ Coats, D. A. (1969.) "Long-term complete parental nutrition", Z Ernahrungswiss, 9(4):401-2. PMID 4983125.
  5. ^ "Key Dates – Faculty of Medicine Online Museum and Archive". Sydney Medical School. 
  6. ^ [1][dead link]
  7. ^ http://www.nrp.org.uk/nrpnews.php[dead link]
  8. ^ "Leading cardiologist appointed to harness world-class research". University of East Anglia. 15 July 2010. 
  9. ^ Jump, Paul (13 December 2012). "Interview – One man, two guvnors and a single vision | General". Times Higher Education. Retrieved 21 October 2013. 
  10. ^ Hare, Julie (18 September 2012). "Andrew Coats to drive Monash–Warwick alliance". The Australian. 
  11. ^ Coats, Andrew J. Stewart (30 October 2012). "Monash–Warwick: what does a global university partnership look like?". The Guardian. 
  12. ^ Coats, A. J.; Conway, J.; Somers, V. K.; Isea, J. E.; Sleight, P. (1989.) "Ambulatory pressure monitoring in the assessment of antihypertensive therapy", Cardiovasc Drugs Ther, 3 Suppl 1:303-11. PMID 2487802.
  13. ^ Daytime ambulatory systolic blood pressure is more effective at predicting mortality than clinic blood pressure. Dawes MG, Coats AJ, Juszczak E. Blood Press Monit. 2006 Jun;11(3):111-8.
  14. ^ Effects of physical training in chronic heart failure. Coats AJ, Adamopoulos S, Meyer TE, Conway J, Sleight P. Lancet. 1990 Jan 13;335(8681):63-6. PMID 1967416
  15. ^ Symptoms and quality of life in heart failure: the muscle hypothesis. Coats AJ, Clark AL, Piepoli M, Volterrani M, Poole-Wilson PA. "Br Heart J" 1994 Aug;72(2 Suppl):S36-9. PMID 7946756
  16. ^ Effect of carvedilol on survival in severe chronic heart failure. Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group. N Engl J Med. 2001 May 31;344(22):1651-8. PMID 11386263
  17. ^ Dickstein K, Kjekshus J; and the OPTIMAAL Trial Steering Committee for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity after acute myocardial infarction: The OPTIMAAL randomized trial. Lancet 2002; 360(9335):752-60 PMID 12241832
  18. ^ Flather MD, Shibata MC, Coats AJ, Van Veldhuisen DJ, Parkhomenko A, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J 2005; 26: 215–25. PMID 15642700
  19. ^ "Coats A – PubMed – NCBI". Ncbi.nlm.nih.gov. 25 March 2013. Retrieved 21 October 2013. 
  20. ^ http://www.msmr.nsw.gov.au/__data/page/21/NSW_Research_-_A_Prescription_for_Health.pdf[dead link]
  21. ^ "News | The University of Sydney". Usyd.edu.au. 6 January 2009. Retrieved 21 October 2013. 
  22. ^ http://telegraph.uk-wire.com/cgi-bin/articles/201012150700209692X.html?epic=IVO[dead link]
  23. ^ http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=10740106[dead link]
  24. ^ "Home". LoneStar Heart, Inc. Retrieved 21 October 2013. 
  25. ^ [2][dead link]
  26. ^ "Financial Report for the Year Ended 30 June 2007". Wearne & Co. 2007. 
  27. ^ "Financial Report for the Year Ended 30 June 2008". Wearne & Co. 2008. 
  28. ^ "Peter Coats". Minter Ellison. 
  29. ^ "Law at Melbourne". Melbourne Law School. November 2003. 
  30. ^ a b "Advisory Board". PsiOxus. Retrieved 21 October 2013. 

External links[edit]